AB Science S.A.
ABSCF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$82.04M
Close$
$-0.07
106.1% downside
Current Fair Value
106.1% downsideOvervalued by 106.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $82.04 Million |
|---|---|
| Enterprise Value | $76.08 Million |
| Earnings per Share | $-0.03 |
| Beta | 1.23 |
| Outstanding Shares | 67,826,080 |
Return
| Return on Equity | 80.73% |
|---|---|
| Return on Assets | -56.61% |
| Return on Invested Capital | -151.50% |
Valuation & Multiples
| P/E Ratio | -6.82 |
|---|---|
| PEG | -9.34 |
| Price to Sales | - |
| Price to Book Ratio | -1.12 |
| Enterprise Value to Revenue | 34.9 |
| Enterprise Value to EBIT | -5.17 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | -0.25 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 9, 2026
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$685,236
Consensus analyst estimateNext Earnings Call
Expected Date
April 23, 2027
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$672,060
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About AB Science S.A.
40 employees
CEO: Stéphane Ledermann
AB Science S.A. is a pharmaceutical firm focused on discovering, advancing, and commercializing protein kinase inhibitors for both human and animal therapeutic applications. The company's primary drug candidate, masitinib, a tyrosine kin...